One potential implication from these findings is that differences in regulating satiation and/or satiety may contribute to the spectrum of Glp1r agonist-induced weight loss in clinical settings
Why the Advanced Recomp Stack Adds CJC/Ipa to Retatrutide Foundation: Retatrutide Retatrutide alone produced the strongest weight-loss results documented in clinical trials: 24.2% mean body weight reduction at 48 weeks in Phase 2 [NEJM 2023] and 28.7% at 68 weeks in Phase 3 (TRIUMPH-4, December 2025)
Weight Loss with Semaglutide, Tirzepatide & Phentermine Tirzepatide (Mounjaro ) is the first and only approved type 2 diabetes medicine of its kindactivating the receptors of two key hormones to help lower blood sugar levels in adults and children 10 years of age and older with type 2 diabetes, along with diet and exercise
Are my digestive symptoms more consistent with inflammation, infection, IBS, food intolerance, medication effects, or another condition
Survodutide, another GLP-1/glucagon dual agonist, shows promising results in Phase 2 trials
Support was provided by National Institutes of Health, National Institute of Neurological Disorders and Stroke Grant K08NS057824